Page 91 - Clinical Olfactory Working Group Consensus Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical olfactory working group consensus statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Olfactory Working Group Consensus Statement Today - Breaking & Trending Today

Brainlab Acquires Mint Medical to Advance Quality and Structure of Data Gathered in Clinical Routine and Research

(1)
Together the companies will increase radiological report automation through AI and Anatomical Mapping and will create unparalleled longitudinal data
Brainlab, a digital medical technology company, announced today the acquisition of Mint Medical GmbH, a Heidelberg-based company that develops image reading and reporting software for clinical routine and research. The acquisition underscores the Brainlab commitment to digital health and aims to improve the structured diagnosis, analysis and treatment of cancer and other diseases to address the demands of modern medicine and personalized treatments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005267/en/
The transformation of our health care system is currently focused in large part on standardizing clinical data through a coding system, commented Stefan Vilsmeier, President and CEO, Brainlab. However, high quality and consistency of such dat ....

United States , Baden Wuberg , Kostenloser Wertpapierhandel , Debbra Verard , Robert Seeger , Matthias Baumhauer , Stefan Vilsmeier , Marketing Communications , Anatomical Mapping , Mint Medical Gmbh , Mint Medical , Brainlab Anatomical Mapping , Brain Lab , Medi Cal , ஒன்றுபட்டது மாநிலங்களில் , ராபர்ட் பார்ப்பவர் , சந்தைப்படுத்தல் தகவல்தொடர்புகள் , உடற்கூறியல் விவரணையாக்கம் , புதினா மருத்துவ கஂப் , புதினா மருத்துவ , மூளை ஆய்வகம் , மேதி கலோரி ,

Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers

Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers
-
Trial will focus on patients without liver metastases, based on encouraging data in Phase Ib/II study
-
Trial targets indications where clinical outcomes can be improved versus standard therapeutic options and immune checkpoint inhibitors ( ICIs )
-
Continued clinical collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to conduct the expanded Phase II study
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the expansion of a randomized, controlled study with TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital tumors (NCT: 03260023) ....

Distrito Federal , United States , United Kingdom , Lucie Larguier , Christophe Le Tourneau , Le Tourneau , Transgene Euronext , Sylvie Berrebi , Maud Brandely , Citigate Dewe Rogerson , Head Of The Department Drug Development , Information Center Statistics , Curie Institute , Merck Kga , Pfizer Inc , Merck Kgaa , Corporate Communications , Information Center Prevention , American Cancer Society , Euronext Paris , Drug Development , Principal Investigator , Chief Medical Officer , Positive Cancers , Artificial Intelligence , Approved Indications ,

Mexico Banks on New Chinese Vaccines to Fight COVID-19 (VIDEO)

Mexico announced it'll receive 12 million doses of China's Sinopharm vaccine and 20 million doses of Coronavac. ....

Mexico City , Distrito Federal , Hong Kong , President Andr , Covid 19 , Sino Pharm , Corona Virus , மெக்ஸிகோ நகரம் , திஸ்திரிதோ கூட்டாட்சியின் , ஹாங் காங் , ப்ரெஸிடெஂட் அன்று , சினோ பார்ம் , கொரோனா வைரஸ் ,

bluebird bio : Provides Updated Findings from Reported Case of Acute Myeloid Leukemia (AML) in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy Program

Message :
Required fields
Analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in clinical study of LentiGlobin for SCD
bluebird bio has initiated process with regulators to resume clinical studies
Company to hold conference call and webcast today, March 10, 2021, 8:00 AM EST
bluebird bio, Inc. (Nasdaq: BLUE) announced today that based on the analyses completed to date, it is very unlikely the Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) reported in its Phase 1/2 (HGB-206) study of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) was related to the BB305 lentiviral vector (LVV).
“In addition to our earlier findings of several well-known genetic mutations and gross chromosomal abnormalities commonly observed in AML in this patient, our latest analyses identified the integration site for the vector within a gene called VAMP4. VAMP4 has no known association with the development o ....

United States , United Kingdom , Philip Gregory , Pharmacovigilance Risk Assessment Committee , European Commission , Drug Administration , European Medicines Agency , Groupc Group , Suspected Unexpected Serious Adverse Reaction , Risk Assessment Committee , Priority Medicines , Product Characteristics , Orphan Drug , Breakthrough Therapy , Bluebird Bio , Inc Stock Exchange , Press Release , Resume Blue , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , பிலிப் கிரெகொரி , மருந்தியல் ஆபத்து மதிப்பீடு குழு , ஐரோப்பிய தரகு , ஆபத்து மதிப்பீடு குழு , ப்ரையாரிடீ மருந்துகள் , ப்ராடக்ட் பண்புகள் ,

Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes

Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes
1c
The study has been designed to define parameters for the upcoming Phase 3 trial planned for 2022
This study follows the promising results of the proof-of-concept Phase 1 trial announced on September 15, 2020
Regulatory News:
Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases, announced today the initiation of a Phase 2 study in type 1 diabetes (T1D). The purpose of the study is to confirm and optimize the safety and efficacy of M1Pram in comparison with insulin lispro (Humalog ....

James Salierno , Olivier Soula , Eli Lilly , Pramlintide Biochaperone , Raimund Gabriel , Truth Group , Mc Services , Adocia Press Relations Europe , Euronext Paris , Universal Registration Document , French Autorit , Press Relations Europe , Investor Relations United States , ஜேம்ஸ் சாலிேறினோ , எலி லில்லி , ரேமூஂட் கேப்ரியல் , ரூத் குழு , ம்ஸீ சேவைகள் , உலகளாவிய பதிவு ஆவணம் , ப்ரெஸ் உறவுகள் யூரோப் , முதலீட்டாளர் உறவுகள் ஒன்றுபட்டது மாநிலங்களில் , நீரிழிவு நோய் ,